Why Did Neuren Pharmaceuticals Limited (ASX:NEU) Report Lower H1 Profit Despite Higher Royalties?

Aditi Sarkar

04 November 2026 11:44 PM AEDT

Why Did Neuren Pharmaceuticals Limited (ASX:NEU) Report Lower H1 Profit Despite Higher Royalties?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Neuren Pharmaceuticals Limited (ASX:NEU) reported H1 2026 Revenue of AUD 42.7 million, up 8% from AUD 39.7 million.
H1 2026 profit after tax fell to AUD 4.9 million from AUD 15.0 million in H1 2025.
DAYBUE Royalty income increased 29% in USD terms to USD 23.3 million, equivalent to AUD 33.2 million.
Research and development expenditure increased AUD 12.5 million to AUD 27.4 million as clinical work advanced.
NEU introduced a Dividend policy and declared a fully franked Interim Dividend of AUD 0.15 per share.

Neuren Pharmaceuticals Limited (ASX:NEU) develops treatments for neurodevelopmental disorders and receives royalties from licensed medicine intellectual property. Its half-year report, signed on 25 August 2026 for the six months ended 30 June 2026, showed increasing royalty receipts alongside a material rise in research spending. The combination lifted revenue but reduced reported profit. The results also introduced a dividend policy, while the company continued clinical development of its investigational NNZ-2591 program.

Royalty Growth and Half-Year Earnings

NEU recorded H1 2026 revenue of AUD 42.746 million, compared with AUD 39.723 million in the corresponding period, representing 8% growth. Royalty income earned from the commercial medicine DAYBUE reached USD 23.3 million, or AUD 33.2 million. The royalty figure increased 29% in U.S. dollars and 17% as reported in Australian dollars.

Despite the higher revenue, profit after tax declined to AUD 4.852 million from AUD 15.031 million. Basic Earnings per share decreased to 3.83 Australian cents from 11.88 cents. The difference between royalty growth and earnings performance reflects the additional costs associated with advancing the development portfolio.

DAYBUE Sales and Licensed-Medicine Income

The half-year report stated that DAYBUE net sales reached USD 226.0 million during H1 2026, up from USD 180.7 million. The medicine generates royalties under a licensing arrangement rather than direct product revenue recorded by NEU. Company disclosures attributed the increase to Demand in the United States and named-patient sales in other markets.

The royalty stream is linked to net sales and contractual terms, so its trajectory depends on commercial performance and the timing of regional launches. The report also described the broader introduction of a powder formulation during 2026. That development concerns the licensed product’s distribution, not a separate medicine developed or sold directly by NEU.

Research and Clinical Trial Spending

Research and development costs increased by AUD 12.5 million to AUD 27.4 million in H1 2026. A significant driver was progression of the Koala Phase 3 study investigating NNZ-2591 in Phelan-McDermid syndrome. The investigational program targets a condition distinct from the approved indication for the royalty-generating medicine.

Corporate and administration costs totalled AUD 3.0 million, while interest income was AUD 5.6 million during the half-year. The company’s development commitments may create further spending before additional products can be commercialised.

Dividend Policy and Capital Allocation

Following the reporting period, NEU declared its first fully franked interim dividend of AUD 0.15 per share under a newly introduced dividend policy. The Record Date was 16 September 2026 and the payment date was 7 October 2026. The company linked the policy to the royalty income generated from DAYBUE.

NEU also reported AUD 3.9 million of on-market share Buybacks during H1 2026, compared with AUD 39.6 million in H1 2025. These decisions illustrate different uses of cash alongside clinical investment. Future distributions will depend on available resources, Business performance and board decisions, while development expenditure remains relevant to the overall funding position.

Key Insights

NEU reported higher H1 2026 revenue and royalty receipts but substantially lower net profit as clinical development spending increased. DAYBUE remained the main commercial source of royalties, while NNZ-2591 required continued research expenditure. The newly declared interim dividend introduced a Shareholder distribution alongside the development strategy.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.